Clinical audit of National Institute of Clinical Excellence (NICE) Technology Appraisal Guidance (TAG) 81 and 82/Clinical Guidelines (CG57) on atopic eczema in children
Keywords:
Atopic eczema, topical corticosteroids, topical calcineurin inhibitors, tacrolimus, pimecrolimusAbstract
Objective To find out how far our current practice complies with the NICE guidelines and to identify any areas in which improvement is needed Patients and methods The audit sample consists of 50 patients. The inclusion criteria include children from birth up to the age of 12 years and diagnosed with atopic eczema Results 100% patients (n=50) in this audit were treated with topical corticosteroids. 100% cases (n=50) were treated in accordance with NICE recommendations. The drug with lowest acquisition cost was prescribed in 31 (62%) cases. None of the 50 patients was prescribed either tacrolimus or pimecrolimus. Conclusions The patients in this audit tended to be young. All patients had either mild to moderate eczema with no cases with severe eczema. All patients responded to treatment regimen comprising topical steroids with none requiring topical calcineurin inhibitors i.e. tacrolimus and pimecrolimus.References
Management of atopic eczema in children from birth up to the age of 12 years. NICE clinical guidelines, CG57 – Issued: Dec 2007.
Atherton DJ. Topical corticosteroids in atopic dermatitis. BMJ. 2003;327:942-3.
Breuer K, Werfel T, Kapp A. Safety and efficiency of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol. 2005;6:65-77.
Ahuja A, Land K, Barnes CJ. Atopic dermatitis. South Med J. 2003;96:1068-72.
Eichenfield LF, Lucky AW, Boguniewicz M et al. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol. 2003;49:1088-95.